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A B S T R A C T
Recombinant human bone morphogenetic proteins (rhBMPs) have past a long journey in human orthopaedic surgery
during the last 15 years. From the first reports of the use of rhBMPs in hostile environments such as critically-sized bone
defects, avascular femoral head necrosis, unstable thoracolumbar vertebral fractures, instability between the atlas and
axis due to rheumatoid arthritis; over the use for nonunions of long bones and the scaphoid, reconstructive and revision
surgeries of the hip, acute fractures, allograft nonunions, congenital pseudarthrosis, and various approaches of lumbar
and cervical spine fusions, rhBMPs overgrow to a safe and reliable device in the treatment of open tibial shaft fractures,
nonunions of long bone fractures, anterior lumbar interbody fusion and revision posterolateral lumbar fusions. System-
atic review of the published literature of rhBMPs is presented.
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Introduction
In 1965, Marshall R. Urist made the seminal discov-
ery that the extracellular matrix of bone contains the ca-
pacity to induce new bone formation by implanting a
substance into extraskeletal sites in a host1 which he
later named bone morphogenetic protein (BMP).
By 1988, the molecular clones had been characterized,
as well as the activities associated with this protein, and
the amino acid sequence from a highly purified prepara-
tion from bone was derived. This led to the isolation and
expression of complementary DNAs, which were recog-
nized as members of the transforming growth factor-b
supergene family. In humans, two of 15 isolated BMP
molecules have been particularly well described, BMP-2
and BMP-7 (also named osteogenic protein-1, OP-1). Both
of them have been isolated, sequenced, and manufac-
tured using the recombinant DNA techniques what al-
lowed a reproducible production of a single BMP, at a
known concentration and purity.
After many animal studies which have illustrated the
potential of BMPs to repair critical-size defects, acceler-
ate a union, enhance spinal fusions, enhances the bone
graft incorporation and the implant fixation, increases
the remodeling and bone ingrowth of bone grafts and
bone substitutes, and heal articular cartilage lesions, the
clinical application of BMPs started2.
The composite device consisting of rhBMP-2 carried
by an absorbable collagen sponge was trademarked as In-
FUSE (Medtronic Sofamor Danek, Memphis, TN, USA)
and the one consisting of rhBMP-7 (OP-1) pre-mixed by
bovine collagen was trademarked as OP-1 Implant (Stryk-
er Biotech, Hopkinton, MA, USA). The addition of 230
mg carboxymethylcellulose (CMC) to the OP-1 Implant
forms OP-1 Putty (Stryker Biotech, Hopkinton, MA,
USA).
The purpose of this work is to give a systematic review
of the use of rhBMPs in regeneration of the skeleton.
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Nonunions and Bone Defects of Long Bones
Despite the intrinsic regenerative and reparative ca-
pacity of bone and the ongoing advances in the treatment
of fractures, impaired healing continues to be one of the
severe complications of fractures.
Cancellous autogenous bone grafting (AUBG) rema-
ins the gold standard procedure used to promote union
by stimulating the local biology at the nonunion site.
However, its limited available quantity, as well as the do-
nor site morbidity and complications, dictated the need
for the development of alternatives in the management
of nonunions and often present bone defects.
The corner stone of rhBMP efficacy in humans was
set by Geesink et al.3 (Table 1). In a previously validated
critically-sized human fibular defect created during high
tibial osteotomy for osteoarthritis of the knee, 6 patients
were treated with rhBMP-7 combined with a collagen
type-I carrier and the other 6 patients were treated with
collagen type-I alone. Five of 6 patients showed forma-
tion of new bone 6 weeks after rhBMP-7 implantation.
None of the fibular defects treated with only the collagen
carrier went on to heal.
At 9 months following the insertion of an intrame-
dullary rod accompanied by rhBMP-7 or AUBG, 81% of
the rhBMP-7 treated tibial nonunions (n=63) and 85% of
those receiving AUBG (n=61) were judged by clinical cri-
teria to have been treated successfully4. There was no
statistically significant difference in outcome between
the two groups of patients at the same time point.
A successful use of rhBMP-7 in the treatment of more
than 20 long bone nonunions was reported5. Later, Pe-
cina et al. additionally reported on a preamputation non-
union of the distal tibia in a patient with 11 previously
failed surgical treatments who healed after implantation
of rhBMP-7 and external fixation by Ilizarov6.
Two clavicular nonunions healed at three months af-
ter the treatment with rhBMP-7, iliac AUBG, internal
fixation and electrical stimulation7.
In addition to rhBMP-7 all the patients with atrophic
humeral diaphyseal nonunions8 went on to an eventual
union including the nonunions in 11 patients treated
with rhBMP-7 without iliac AUBG.
Both, clinical and radiological union occurred after
the treatment with rhBMP-7 and different fixation pro-
cedures in 24 upper and lower limb atrophic nonunions
(92.3%) and in two of them after second rhBMP-7 appli-
cation, within a mean time of 4.2 months and 5.6 months,
respectively9.
In evaluation of the type of indications and the effi-
cacy of clinical applications of rhBMP-7 in the United
Kingdom, the overall success rate was 82% (535 cases)10.
In 74% of cases, the application was combined with
AUBG, whilst in 23% cases rhBMP-7 was used alone.
Radiographic successful outcome was recorded in 88
patients (83.8%) with nonunion in various sites with the
average healing time of 7.9 months11.
The rhBMP-7 implant (n=16) was more efficacious
that platelet rich plasma (PRP) preparations (n=13) in
the treatment of long bone nonunions or/and critical size
bone defects, as there was a significant failure rate of
38.5% versus 6.2% between the PRP and rhBMP-7 treat-
ed patients, respectively12.
Scaphoid Nonunion
The patients with scaphoid avascular and necrotic
proximal pole nonunions were randomly assigned to three
treatment groups: (1) iliac AUBG (n=6), (2) iliac AUBG
+ rhBMP-7 (n=6), and (3) iliac allogeneic bone graft
(ALBG) + rhBMP-7 (n=5)13. The rhBMP-7 improved the
performance of both AUBG and ALBG and reduced the
radiographic healing time to 4 weeks as compared to 9
weeks in group 1. Helical CT scans and scintigraphy
showed that in rhBMP-7-treated patients sclerotic bone
was replaced by a well-vascularized bone.
Congenital Pseudarthrosis of the Tibia
Treatment of congenital pseudarthrosis is challeng-
ing and often disappointing and unsatisfactory outcomes
may lead to amputation14.
The use of rhBMP-7 in conjunction with intrame-
dullary stabilization (two rods and three 2-mm K-wires)
and AUBG in a boy with atrophic tibial pseudarthrosis
associated with neurofibromatosis with 9 unsuccessful
previous operations resulted with the bone union after 5
weeks15.
Another successful healing was reported 5 months af-
ter radical resection of sclerotic tibial segments, Ilizarov
fixation and administration of rhBMP-7 in a patient with
congenital pseudarthrosis of the tibia after 12 unsuccess-
ful surgeries16.
Allograft Nonunions
The results of 6 femoral allograft nonunions in pa-
tients who underwent resection of malignant bone tu-
mors and allograft bone transplantation were analyzed
one to 5 years following application of either rhBMP-2
(n=3) or rhBMP-7 combined with corticocancellous allo-
graft (n=3) at the nonunion site17. There was neither
healing of allograft fractures, nor union of allograft-host
junction at a minimal follow-up of 12 months. There was
an elongation or enlargement of the callus from the host.
There was no tumor recurrence with the use of rhBMPs
after a mean follow-up of 39±25 months.
Fractures
The treatment of open tibial shaft fractures continues
to be associated with high rates of delayed union and
nonunion18. Thus, the goal of the initial fracture treat-
ment should be to increase the likelihood of union and re-
duce the risk and cost of secondary procedures.
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TABLE 1
LIST OF PUBLICATIONS RELATED TO TREATMENT OF LONG BONE NONUNIONS, BONE DEFECTS, SCAPHOID NONUNIONS, CONGENITAL
PSEUDARTHROSIS OF THE TIBIA, ALLOGRAFT NONUNIONS, FRACTURES, OSTEONECROSIS OF THE FEMORAL HEAD, RECONSTRUCTIVE
AND REVISION SURGERY OF THE HIP WITH RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEINS (rhBMPs) INCLUDED
1st Author and Year Type of the Study Localization and kind of defect Sample Size rhBMP/Carrier Dose of rhBMP
Geesink3 (1999) PRDBS critically-sized fibular defect 24 rhBMP-7/CT-1 2.5 mg
Schedel23 (2000) MRCT avascular femoral head necrosis 6 rhBMP-2/blood
mixture
?
Friedlaender4 (2001) CPRPBMCCT
FDA/IDA
124 established tibial nonunions 122 rhBMP-7/CT-1 3.5 mg
Cook24 (2001) CCS reconstructive surgery of the hip 4 rhBMP-7/CT-1 3.5 mg
Pecina5 (2001) R resistant nonunions of femur,
tibia, radius
20 rhBMP-7/CT-1 OP-1 device
(3.5 mg)
Govender19 (2002) PRCSBS open tibial shaft fractures 450 rhBMP-2/CT-1 6–12 mg
Pecina6 (2003) CR pre-amputation
non-union of the distal tibia
1 rhBMP-7/CT-1 OP-1 device
(3.5 mg)
Evans7 (2004) CR clavicular midshaft nonunion 2 rhBMP-7/CT-1 OP-1 device
(3.5 mg)
Delloye17 (2004) CT 2 allograft fracture nonunions
and 4 nonunions at the
allograft-host junction
5 rhBMP-2 or
rhBMP-7
12 mg of
rhBMP-2,
7 mg of rhBMP-7
Bong8 (2005) ISMPCS
FDA/IDA
atrophic humeral diaphyseal
nonunions
23 rhBMP-7/CT-1 3.5 mg
Dimitriou9 (2005) CT 10 tibial, 8 femoral, 3 humeral,
3 ulnar, 1 patellar, and
1 clavicular nonunion
25 rhBMP-7/CT-1 3.5 mg
Giannoudis10 (2005) MCS nonunions of tibia (42%), femur
(29%), humerus (11%), clavicle
(6%), radius (5%), scaphoid (4%),
ankle (4%), olecranon (4%), ulna
(3%), tibial plateau (2%), fibular
graft (1%) and patella (0.1%)
653 rhBMP-7/? 3.5 mg
Fabeck15 (2006) CR congenital pseudarthrosis
of the tibia
1 rhBMP-7/CT-1 3.5 mg
Bilic13 (2006) PRDBCPS proximal pole scaphoid nonunion 18 rhBMP-7/CT-1 3.5 mg
Karrholm25 (2006) CCOS 20 acetabular revisions and 41
femoral revisions
61 rhBMP-7/
CT-1 (?) (MAB)
OP-1 device
(3.5 mg)
Anticevic16 (2006) CR congenital pseudarthrosis
of the tibia
1 rhBMP-7/CT-1 OP-1 device
(3.5 mg)
Swiontkowski20 (2006) SADCF2PRS open tibial shaft fractures 510 rhBMP-2/CT-1 6–12 mg
Jones21 (2006) PRCT
FDA/IDA
tibial diaphyseal fracture and
a residual cortical defect
30 rhBMP-2/CT-1 12 mg
Calori12 (2006) PRCS long bone nonunions, critical size
bone defects, 10 tibia, 7 femur,
5 humerus, 4 ulna, 3 radius
29 rhBMP-7/CT-1 3.5–7 mg
Ronga11 (2006) ORNRS 46 tibial, 23 femoral, 20
humeral, 6 radial, 5 ulnar,
3 forearm, and 2 clavicular
nonunions
105 rhBMP-7/? ?
PRDBS – prospective, randomized, double-blind study, MRCT – multi-center randomized clinical trial, CPRPBMCCT – controlled,
prospective, randomized, partially blinded, multi-center clinical trial, FDA/IDA – Food and Drug Administration approved Investiga-
tional Device Exemption, CCS – clinical cases study, R – review, PRCSBS – prospective, randomized, controlled, single-blind study, CR
– case report, CT – clinical trial, ISMPCS – industry sponsored multi-center prospective clinical study, MCS – multicenter clinical
study, PRDBCPS – prospective, randomized, double blind, clinical pilot study, CCOS – case-control study, SADCF2PRS – subgroup
analysis of data combined from two prospective randomized studies, PRCT – prospective, randomized, controlled trial, PRCS – pro-
spective, randomized, clinical study, ORNRS – observational, retrospective, non-randomized study, rhBMP-7 – recombinant human
Bone Morphologic Protein-7, CT-1 – collagen type 1, rhBMP-2 – recombinant human Bone Morphologic Protein-2, OP-1 device – com-
mercial composite device consisting of rhBMP-7/CT1 (Stryker Biotech, Hopkinton, MA, USA), MAB – morselized allograft bone
Govender et al. demonstrated in multicenter study
that the use of the rhBMP-2 implant was safe and, when
1.50 mg/mL was used, significantly superior to the stan-
dard of care in patients with an open fracture of the tibia
who were randomized to receive either the standard of
care (intramedullary nail fixation and routine soft-tissue
management, the control group) (n=150), the standard of
care and an implant containing 0.75 mg/mL of rhBMP-2
(n=151), or the standard of care and an implant contain-
ing 1.50 mg/mL of rhBMP-2 (n=149)19. From the 94% of
all patients who were available at 12 months follow up,
the 1.50-mg/mL rhBMP-2 treated patients had a 44% re-
duction in the risk of failure (i.e. secondary intervention
because of delayed union), significantly fewer invasive
interventions (e.g., bone-grafting and nail exchange),
and significantly faster fracture-healing than did the
control patients. Significantly more patients treated with
1.50 mg/mL of rhBMP-2 had the fracture healing at the
postoperative visits from ten weeks through twelve months.
Compared with the control patients, those treated with
1.50 mg/mL of rhBMP-2 also had significantly fewer
hardware failures, fewer infections (in association with
Gustilo-Anderson type-III injuries), and faster wound-
-healing (83% compared with 65% had wound-healing at
six weeks). A subgroup analysis of the data from previous
study and from another one with the same study design
was conducted to investigate more clearly mentioned sig-
nificant reduction in the rate of infection in the type-III
open fractures treated with rhBMP-2 and the reduction
of the rate of secondary intervention with the addition of
rhBMP-2 in patients treated with reamed as well as
unreamed intramedullary nailing20.
The patients with a tibial diaphyseal fracture and a
mean length of residual cortical defect 4 cm who were
randomly assigned to receive either allograft with 1.50
mg/mL rhBMP-2/sponge or traditional AUBG for staged
reconstruction of the tibial defect indicated that the two
treatments were equally effective as 13 patients treated
with rhBMP-2/allograft and 10 with autograft had heal-
ing without further intervention21.
Osteonecrosis of the Femoral Head
Surgical treatment for lower stages of the disease in-
cludes core decompression, bone grafting, and osteotomy22.
In patients with avascular femoral head necrosis who
received rhBMP-2 (n=3) after decompression of the core,
regression was observed in one patient (from ARCO IIc to
I) and in the other two deceleration of progress of illness23.
Two of three patients who did not receive rhBMP-2 after
decompression had a progression of the disease (from
ARCO III to IV–V and from ARCO IIa to IIIb).
Reconstructive and Revision Surgery
of the Hip
The challenges of complex THA and even more of re-
vision surgery of the hip include bone loss in the proxi-
mal femur and acetabulum and deformity, cortex perfo-
ration, and periprosthetic fracture.
The initial cases of the use of rhBMP-7 in conjunc-
tions with morcellized ALBG or cortical strut ALBG for
revision of the previously failed proximal femoral allo-
grafts, deficient proximal femurs, an absent femoral cor-
tex and acetabular reconstruction were successful due to
the greater and earlier new bone formation in the more
challenging biologic environment compared to allograft
bone alone24.
Recently, rhBMP-7 mixed with morselized allograft in
hip revisions did not reveal any significant difference in
the acetabular cup migration between the study and
standard care of treatment patients25. The four sockets
of 10 in the rhBMP-7 treated patients were classified as
radiographically loose after 5 years and 2 of them were
revised after 5 years. One stem of 11 in the rhBMP-7
group loosened and was revised during the third year of
observation.
Spinal Surgery
The two primary drawbacks in performing a spinal
fusion are the morbidity of harvesting iliac AUBG which
is needed in almost all instances and the relatively high
frequency of pseudarthrosis.
In an effort to eliminate the need to harvest bone
graft from the iliac crest and to reduce the incidence of
the nonunion, a search for bone graft substitutes has in-
tensified as shown in Table 2.
Vertebral Fractures
The first published use of BMPs in 5 patients with un-
stable thoracolumbar burst fractures has been disap-
pointing, as the rhBMP-7/sponge was not capable of in-
ducing a sufficient early structural bone support26. There
were even indications to suggest that application of
rhBMP-7 sponge at a fracture site in humans in some
cases may result in an inappropriate enhancement of
bone resorption as the primary event.
Anterior Spinal Interbody Fusion (ASIF) –
Lumbar Spine
Solid fusion was achieved in 11 patients 6 months af-
ter the treatment with rhBMP-2/collagen sponge inside
two tapered titanium interbody fusion cages during the
lumbar ASIF27.
Solid radiologic fusion was achieved in all 21 patients
who were available for follow-up at 6 months after the
laparoscopic lumbar ASIF with tapered titanium fusion
cages filled with rhBMP-228.
The higher fusion rate (94.5 vs. 88.7%) remained after
two years of a follow up in 143 patients who had lumbar
ASIF using rhBMP-2 within tapered titanium interbody
cages versus 136 patients who received iliac AUBG29.
The data from previous two studies28,29 and an unpub-
lished study of a similar large-scale clinical trial with a
total of 679 patients were integrated to check the statistical
T. Smoljanovi} et al.: Regeneration of the Skeleton by rhBMPs, Coll. Antropol. 31 (2007) 3: 923–932
926
T. Smoljanovi} et al.: Regeneration of the Skeleton by rhBMPs, Coll. Antropol. 31 (2007) 3: 923–932
927
TABLE 2
LIST OF PUBLICATIONS RELATED TO TREATMENT OF SPINAL DISORDERS WITH RECOMBINANT
HUMAN BONE MORPHOGENETIC PROTEINS (rhBMPs) INCLUDED
1st Author and Year
Type of
the Study
Kind of spinal damage
Sample
Size
rhBMP/Carrier Dose of rhBMP/Level
Laursen26 (1999) PS SL unstable burst FR 5 rhBMP-7/CT-1 2.5 mg
Boden27 (2000) PRCCTP
FDA/IDA
SL lumbar DDD 14 rhBMP-2/CT-1 from 3.9 to 7.8 mg
1.50 mg/mL
Kleeman28 (2001) PCNRS
FDA/IDA
SL DDD or LG SLI 22 rhBMP-2/CT-1 from 4.2 to 8.4 mg
1.50 mg/mL
Burkus29 (2002) MPRNBS SL lumbar DDD 279 rhBMP-2/CT-1 from 4.2 to 8.4 mg
1.50 mg/mL
Johnsson48 (2002) PRS L5 SLO, GR 1 or 2 20 rhBMP-7/CT-1 7 mg
Boden49 (2002) PRCPT SL DDD or SLI GR 1 25 rhBMP-2/BCP 40 mg
Baskin38 (2003) PRCCTP
FDA/IDA
SL or 2L cervical DDD 33 rhBMP-2/CT-1 0.6 mg
1.50 mg/mL
Burkus30 (2004) MPRNBS
FDA/IDA
SL lumbar DDD 46 rhBMP-2/CT-1 from 8.4 to 12 mg
1.50 mg/mL
Burkus30 (2004) IAMCS SL DDD or LG SLI 679 rhBMP-2/CT-1 from 4.2 to 8.4 mg
1.50 mg/mL
Burkus30 (2004) MPRNBS
FDA/IDA
SL lumbar DDD 44 rhBMP-2/CT-1 from 8.4 to 12 mg
1.50 mg/mL
Lanman39 (2004) PPS SL, 2L or 3L cervical DDD 20 rhBMP-2/CT-1 ?
1.50 mg/mL (IBG)
Lanman42 (2004) PCT discogenic pain, SLI GR 1,
nonunion from previous surgery
43 rhBMP-2/CT-1 ?
1.50 mg/mL (IBG)
Kuklo34 (2004) CCS lumbar DDD, isthmic SLI, revision
surgeries, failed-back syndrome
35 rhBMP-2/CT-1 4.2 mg
1.50 mg/mL (IBG)
Mummaneni43 (2004) RCR DDD or LG SLI 44 rhBMP-2/CT-1 8.4 mg
1.50 mg/mL (IBG)
Haid47 (2004) PRNBS
FDA/IDA
SL DDD or LG SLI 67 rhBMP-2/CT-1 from 4 to 8 mg
1.50 mg/mL
Vaccaro50 (2005) MCPS SL LG SLI 12 rhBMP-7/CT-1 +
CMC
7 mg
Schwender44 (2005) CS DDD with DH or SLI or
Chance-type seat belt FR
49 rhBMP-2/CT-1 ?
Boakye40 (2005) RECT acute DH, cervical SLO, ossification
of the PLL, PA after a prior ACDF,
SCC and DH, fall-related C7-T1
subluxation
24 rhBMP-2/CT-1 » 1 or 2.1 mg
1.50 mg/mL (IBG)
Glassman52 (2005) PRNBS
FDA/IDA
SL DDD or LG SLI 74 rhBMP-2/
CT-1 and CRM
40 mg
2 mg/mL
Luhmann37 (2005) PSNCS
FDA/IDA
adult spinal deformity 70 rhBMP-2/CT-1 or
CRM and BCP
from 4 to 40 mg
group 1 mean 10.8 mg
group 2 mean 13.7 mg
group 3 mean 28.6 mg
Vaccaro51 (2005) PRCMCS
FDA/IDA
SL LG SLI 36 rhBMP-7/CT-1 +
CMC
7 mg
Villavicencio45
(2005)
RCS lumbar DDD, spinal instability,
spinal stenosis, FJA, degenerative
SLI
74 rhBMP-2/CT-1 from 4.2 to 12 mg
1.50 mg/mL (IBG)
Burkus31 (2006) MPRNBS
FDA/IDA
SL lumbar DDD 131 rhBMP-2/CT-1 from 8.4 to 12 mg
1.50 mg/mL
Wang36 (2006) RCR SL lumbar DDD 32 rhBMP-2/CT-1 ?
1.50 mg/mL (IBG)
Hansen33 (2006) CR lumbar DDD 1 rhBMP-2/CT-1 4.8 mg
(continued on next page)
superiority of rhBMP-2/sponge to autograft used inside
the threaded intervertebral fusion cagd30. The fusion
success rate in the combined rhBMP-2 treated patients
was 94.4% (201 of 213) at two years after surgery com-
pared to 89.4% (252 of 282) in the autograft treated pa-
tients. At the same time, in the autograft open patients,
nearly a third (32%) continued to have some pain at their
harvest site.
The rhBMP-2 within threaded cylindrical titanium
cages had also superior results compared with the same
cage filled with autograft30 during lumbar ASIF.
After the successful use of rhBMP-2 inside the tita-
nium threaded intervertebral fusion cage in patients who
have undergone lumbar ASIF, the use of structural thre-
aded cortical allograft bone dowels filled with rhBMP-2/
sponge was investigated. At the final two-year radio-
graphic follow-up examination, 99% of the patients in the
study group (n=79) had evidence of a fusion compared to
76% of control patients (n=52). At the same time the
pain at the donor site of the iliac bone graft was observed
to persist in a 46.5% of control patients. Thorough radio-
graphic assessment of the incorporation of the allograft
and new bone formation using serial thin-slice CT scans
of these patients at 12 months revealed that 14 of the in-
vestigational patients (18%) developed a transient, local-
ized area of bone remodeling within the vertebral body
adjacent to the allograft dowel31. These radiolucent areas
had resolved by 24 months after surgery without of any
effect on the clinical outcomes.
Similar bone resorption within the vertebral body but
after transforaminal lumbar interbody fusion (TLIF)
with placement of rhBMP-2 within the disc space with a
variety of interbody fusion cages, allografts and addi-
tional instrumentation posteriorly was noticed in 22 of
the 32 levels reviewed (69%) by CT scans three months
after surgery32.
The connection between the last two studies and oth-
ers where different degrees of resorption of the vertebrae
were observed, was an additional rhBMP-2 sponge which
was placed adjacent to the interbody implant in direct
contact with the vertebral endplates and more impor-
tantly in all this studies an early (under one year) CT fol-
low up had been performed26,31–35.
As mentioned, a resorptive response resembling infec-
tion was noticed in a patient within the interbody space
and adjacent disc spaces in the early months following
the lumbar ASIF with a femoral ring allograft (FRA)
filled with an rhBMP-2/sponge33.
Further on, it was found that the use of rhBMP-2 did
not enhance the fusion rate in the stand-alone lumbar
ASIF with FRAs compared with FRAs filled with iliac
AUBG35. Although, without statistical significance due
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1st Author and Year
Type of
the Study
Kind of spinal damage
Sample
Size
rhBMP/Carrier Dose of rhBMP/Level
Pradhan35 (2006) PCS SL lumbar DDD 36 rhBMP-2/CT-1 ?
1.50 mg/mL (IBG)
Singh53 (2006) PSICCMCS SL-3L level LG SLI 52 rhBMP-2/CT-1 12 mg
1.50 mg/mL (IBG)
Anand46 (2006) PCS SL-2L DDD with or without SLI 100 rhBMP-2/CT-1 8.4 mg (4.2 mg)
1.50 mg/mL (IBG)
McClellan32 (2006) RRE SL-2L DDD with or without
radiculopathy
26 rhBMP-2/CT-1 from 4.2 to 12 mg
1.50 mg/mL (IBG)
Dimar54 (2006) PRNBS
FDA/IDA
SL lumbar DDD or LG SLI 98 rhBMP-2/CRM 40 mg
2.0 mg/mL
PS – pilot study, PRCCTP – prospective, randomized, controlled, clinical pilot trial, FDA/IDA – Food and Drug Administration ap-
proved Investigational Device Exemption, PCNRS – prospective, controlled, nonrandomized study, MPRNBS – multicenter, prospec-
tive, randomized, nonblinded study, PRS – prospective, randomized study, PRCPT – prospective, randomized, clinical, pilot trial,
IAMCS – an integrated analysis of multiple clinical studies, PPS – prospective study, PCT – prospective, clinical trial, CCS – consecu-
tive case series, RCR – retrospective chart review, PRNBS – prospective, randomized, nonblinded study, MCPS – multicenter, clinical,
pilot study, CS – clinical study, CR – case report, RECT – retrospectively evaluated clinical trial, PSNCS – prospective, single-center,
nonblinded, clinical study, PRCMCS – prospective, randomized, controlled, multicenter clinical study, RCS – retrospective clinical
study, PCS – prospective, cohort study, PSICCMCS – prospective, single institution, clinical case-matched cohort study, RRE – retro-
spective, radiographic evaluation, SL – single-level, FR – fracture, rhBMP-7 – recombinant human Bone Morphologic Protein-7, CT-1 –
collagen type 1, DDD – degenerative disc disease, rhBMP-2 – recombinant human Bone Morphologic Protein-2, LG – low grade, GR –
grade, SLI – spondylolisthesis, SLO – spondylosis, 2L – two level, 3L – three level, IBG – Infuse bone graft (Medtronic Sofamor Danek)
(»kit» of rhBMP-2/InFUSE may contain anywhere from 4 to 12 mg), CMC – carboxymethylcellulose, DH – disc herniations, PLL – pos-
terior longitudinal ligament, PA – pseudarthrosis, ACDF – anterior cervical discectomy and fusion, SCC – spinal cord contusion, CRM
– compression resistant matrix carrier (a carrier consisting of bovine collagen and tricalcium/hydroxyapatite), BCP – biphasic calcium
phosphate granules, FJA – facet joint arthropathy
TABLE 2
LIST OF PUBLICATIONS RELATED TO TREATMENT OF SPINAL DISORDERS WITH RECOMBINANT
HUMAN BONE MORPHOGENETIC PROTEINS (rhBMPs) INCLUDED
(continued from the previous page)
to early termination of the recruitment of rhBMP-2
treated patients after suboptimal results were noted, a
trend was toward a higher nonunion rate with rhBMP-2.
The rhBMP-2 was used within titanium cages during
lumbar ASIF as the first part of lumbar stabilization fol-
lowed by a rigid spinous process plate in 21 patients
which was compared to the bilateral pedicle screw (BPS)
fixation in 11 patients36.
The rhBMP-2 was also used in adult patients with spi-
nal deformities in multilevel anterior and posterior fu-
sions with a minimum 1-year follow-up37. For the ante-
rior fusion group (n=46) with titanium mesh cages and
protected with posterior instrumentation, operative lev-
els were deemed fused in 89 of the 93 (96%) levels. For
the posterior, i.e. posterolateral fusion group (n=41), a
solid fusion was assessed in 110 of 118 (93%) operative
levels. For the »compassionate-use« patients, i.e. patients
who had prior surgeries, prior iliac harvesting, and sub-
stantial comorbidities the overall fusion rate was 100%
(52 of 52 operative levels).
Anterior Spinal Interbody Fusion (ASIF) –
Cervical Spine
After the application of rhBMP-2 had demonstrated
consistent and clear osteoinduction in lumbar ASIF the
use in cervical ASIF started.
All patients treated with allograft fibular graft filled
either with rhBMP-2 sponge (n=18) or with iliac AUBG
(n=15) during cervical ASIF with anterior cervical plate
had solid fusions 6, 12, and 24 months after surgery38.
The bridging bone was demonstrated in all patients
three months after the cervical ASIF with rhBMP-2 con-
tained within a poly(L-lactide-co-D,L-lactide) bioabsorb-
able implants with anterior cervical plate39.
Solid fusion was present in all patients who had un-
dergone cervical ASIF involving the placement of poly-
etheretherketone (PEEK) spacers filled with rhBMP-2
and anterior cervical plating and who were available for
12 to 16 months follow-up40.
After these promising results without major adverse
effects except for new heterotopic bone formation38,40,
dysphagia in three patients39,40, transient recurrent la-
ryngeal nerve injury, transient C-5 paresis, and cerebro-
spinal fluid leakage40, investigators paid more attention and
reported several complications after the use of rhBMP-2 in
cervical ASIF. Bennett et al. consider that the large BMP
dose in the cervical spine was not needed as they success-
fully used in hundreds of their patients a dose of 1.05 mg
of rhBMP-2 placed in the center of an interbody graft for
the cervical ASIF without deleterious side effects41.
Transforaminal Lumbar Interbody Fusion
(TLIF)
After the successful start of use of the rhBMP-2 in
ASIF it started to be used also in TLIF procedures.
Successful interbody fusion was observed in 98% of 41
patients 6 months after TLIF with rhBMP-2/sponge con-
tained within a poly(L-lactide-co-D,L-lactide) bioabsorb-
able implants and various posterior spinal fixation sys-
tems42.
In an another study, where the same absorbable inter-
body spacers were used with an additional rhBMP-2 con-
taining sponge sometimes placed in front of the interbody
spacer the radiographic fusion rate for the 22 patients re-
ported (mean duration 12.4 months) was 87.2%34.
TLIF involving rhBMP-2 within and in front of in-
terbody spacers promoted a more rapid fusion43.
The rhBMP-2 was used for augmentation of local
AUBG or allograft bone in few patients who underwent
the minimally invasive TLIF with bilateral percutaneous
pedicle screw–rod placement and the structural support
was achieved with the allograft bone or interbody cag-
es44. At a minimum of 18 months’ follow-up, all cases ap-
peared to have solid radiographic fusions.
The efficacy of rhBMP-2 was not dependent on which
approach was used, minimally invasive (n=43) or open
approach (n=31), or the number of spinal levels (one,
two or three-level) that were treated with TLIF as the ra-
diographic fusion rate in all patients was 100% at 12 and
24 months after the surgery45.
The fusion rate was 100% using rhBMP-2 and the
structural allograft with a local AUBG during cantilever
TLIF technique with pedicle screw fixation and the
PLSF at two years follows up46.
Posterior Lumbar Interbody Fusion (PLIF)
Although the fusion rate of PLIF with stand-alone cy-
lindrical threaded titanium fusion cages was not statisti-
cally different at 2 years follow up, the rhBMP-2 treated
patients (n=34) the fusion rate of 92.3% was higher than
in iliac AUBG patients (n=33) at 77.8%47.
Posterolateral Spinal Fusion (PLSF)
There was no significant difference between the results
of noninstrumented PLSF augmented with the rhBMP-7
implant (n=10) contrary to fusion with AUBG (n=10)48.
Although rhBMP-7 demonstrated a bone-forming response
in 9 of 10 patients, the rhBMP-7 implant did not yield
better formation of stabilizing bridging bone than the
autograft bone in human noninstrumented PLSF.
Boden et al. considered that the mentioned clinical
failure with BMPs during PLSF likely resulted from
suboptimal carrier matrices used to deliver the BMP and
a failure to recognize the requirement for the substan-
tially increased doses of BMP needed to induce bone for-
mation in humans, as compared with other tested ani-
mals in who BMPs demonstrated consistent success49.
Accordingly, the authors used for PDSF 20 mg of rhBIP-2
on each side which was delivered on a carrier consisting
of 60% hydroxyapatite and 40% tricalcium phosphate
granules. The fusion rate was 40% (2/5) in the auto-
graft/pedicle screw fixation treated patients and 100%
(20/20) in patients treated with rhBMP-2 with or without
the pedicle screw fixation.
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In the study of uninstrumented PLSF augmented
with rhBMP-7 as an adjunct to the iliac AUBG and mixed
with the carboxymethylcellulose (CMC) at two year fol-
low up 50% of 10 available patients with radiographic fol-
low-up achieved a solid fusion. The bridging bone on the
anteroposterior film was observed in 70% of patients50.
Vaccaro et al. reported on the randomized study of
PLSF without instrumentation augmented with rhBMP-
-7 (n=24) or AUBG (n=12)51. At two year time point ra-
diographic fusion was observed in 55% patients treated
with rhBMP-7 and 40% patients treated with AUBG and
this difference still was not statistically significant.
The instrumented PLSF augmented by rhBMP-2 in
conjunction with HA-TCP compression resistant matrix
(CRM) (n=36) or iliac AUBG (n=36) was compared by
CT scans52. CT scans at 6 and 12 months were graded
from grade 1–5. Mean fusion grade at 6 months after sur-
gery was 4.35 in the rhBMP-2/CRM treated patients ver-
sus 3.09 in the iliac AUBG treated patients. At one year
after surgery mean fusion grade was 4.62 in the rhBMP-
-2/CRM treated patients versus 3.77 in the iliac AUBG
treated patients.
Two years after instrumented PLSF with either
rhBMP-2 wrapped around a bulking agent (local and iliac
AUBG) (n=52) or iliac AUBG 97% of rhBMP-2 treated
patients had a fusion compared to 77% in iliac AUBG
treated patients53.
In the similar study, but with rhBMP-2/CRM instead
of rhBMP-2 wrapped around a bulking agent, in the
rhBMP-2/CRM treated patients the fusion rate (88%;
n=53) was significantly higher than in the iliac AUBG
treated patients (73%; n=45) at a two year follow up54.
Overview
The rhBMP-7 was successfully used in a human fibu-
lar defect and nonunions of the tibia and the tibial pla-
teau, clavicle, humerus, femur, ulna and olecranon, ra-
dius and the scaphoid. Incidentally, the use of rhBMP-7
in nonunions of ankle, patella and fibular graft and in
the other surgical procedures as periprosthetic fracture
treatment and osteotomies, enhancement of fracture
healing following acetabular reconstruction, distraction
osteogenesis, free fibular graft and arthrodesis of joints
were reported.
Congenital pseudarthrosis of the tibia was success-
fully healed by rhBMP-7 in two published case reports,
but in a third report of 5 cases, the use of rhBMP-7 was
not enough to overcome the poor healing environment
that is associated with congenital the disease.
The rhBMP’s (rhBMP-2 and rhBMP-7) alone were not
sufficient to achieve healing in allograft nonunions and
fractures following wide resection including periosteum
and soft tissues, and adjuvant therapies.
The use of rhBMP-2 was significantly superior to the
standard of care in reducing the frequency of secondary
interventions and the overall invasiveness of procedures,
accelerating fracture and wound-healing, and reducing
the infection rate in patients with an open fracture of the
tibia. The rhBMP-2 was also effective for reconstruction
of diaphyseal tibial fractures with cortical defects, too.
Regression and deceleration of progress of osteonec-
rosis of the femoral head was observed in patients treat-
ed with core decompression and rhBMP-2.
The results of use of rhBMP-7 in reconstructive sur-
gery of the hip were currently doubtful.
The first use of rhBMPs in spinal surgery resulted in
formation of insufficient structural bone support in pa-
tients with unstable thoracolumbar burst fractures caus-
ing vertebral resorption.
However, rhBMP-2 was successfully used for ALIF
when rhBMP-2/sponge was placed either inside threaded
intervertebral fusion cages or cylindrical threaded corti-
cal allograft dowels with or without other instrumenta-
tion. The use of FRA filled with rhBMP-2 for ALIF was
connected with an early dislodgment of the interbody
graft, with a resorptive response of rhBMP2 simulating
infection and finally with a higher nonunion rate com-
pared with FRA filled with AUBG. Recently, the resorp-
tion of vertebral bodies was observed by CT during the
first months of the follow up after the use of an addi-
tional rhBMP-2 sponge in a direct contact with the verte-
bral endplates. The patients with cervical spine pathol-
ogy were successfully treated with cervical ASIF with
rhBMP-2.sponge `laced either inside the allograft fibular
grafts or poly(L-lactide-co-D,L-lactide) bioabsorbable im-
plants or PEEK spacers. Lately, it was observed in two
retrospective studies that rhBMP-2 used for cervical ASIF
had caused complications in patients mostly as dramatic
swelling.
The use of rhBMP-7 for atlanto-axial posterior fusion
after wire fixation in patients on chronic steroid treat-
ment was not successful. The success with rhBMP-7 was
achieved in patients with medical risk factors that would
inhibit osseous fusion during cervical and lumbar post-
erolateral fusions with or without instrumentation, CEC
or CRM. The rhBMP-2 was also successfully used to
achieve PHLF.
The rhBMP-2 alone or contained within a poly(L-
-lactide-co-D,L-lactide) bioabsorbable implants or other
interbody cages together with various spinal fixation sys-
tem was successfully used for TLIF. The use of rhBMP-2
for PLIF was successful, but it was connected to the new
bone formation extending outside the disc space and into
the spinal canal or neuroforamina.
Finally, rhBMP-2, i.e. InFUSE is approved by the FDA
for anterior lumbar interbody fusion (ALIF) when used
with an lumbar tapered titanium interbody fusion device
(LT-Cage; Medtronic Sofamor Danek, Memphis, TN)55
and for treating acute, open tibial shaft fractures that
have been stabilized with IM nail fixation56. The rhBMP-
-7, i.e. OP-1 Implant is currently approved by the FDA for
treatment of nonunions of long bone fractures57 and OP-1
Putty is approved as a substitute for autogenous bone
when attempting revision posterolateral lumbar fusions58.
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REGENERACIJA KOSTURA REKOMBINIRANIM LJUDSKIM KO[TANIM MORFOGENETSKIM
PROTEINIMA
S A @ E T A K
Rekombinirani ljudski ko{tani morfogenetski proteini (recombinant human Bone Morphogenetic Proteins, rhBMP)
su pre{li dug put tijekom posljednjih 15 godina primjene u ljudskoj ortopediji. Od prvih izvije{}a o primjeni rhBMP-a u
»neprijateljskim« uvjetima kao {to su kriti~ni ko{tani defekti, avaskularne nekroze glave bedrene kosti, nestabilni tora-
kolumbarni prijelomi kralje{aka, nestabilnosti izme|u atlasa i aksisa kao posljedica reumatskog artritisa; preko ko-
ri{tenja kod pseudartroza dugih kostiju i skafoida, rekonstruktivnih i revizijskih operacija kuka, akutnih prijeloma,
pseudartoza ko{tanih alogeni~nih presadaka, kongenitalnih pseudartroza, te svih poznatih pristupa fuziji vratne i lum-
balne kalje`nice, rhBMP-ovi su se razvili do sigurnog i pouzdanog sredstva u lije~enju otvorenih prijeloma tibije, pseu-
dartroza dugih kostiju, prednje interkorporalne fuzije lumbalnih kralje`aka i revizijskih posterolateralnih fuzija lu-
malne kralje`nice. Prikazujemo sistemati~an pregled objavljene literature o rhBMP-u.
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